Corvus Pharmaceuticals Priced, Nasdaq: CRVS

Developing checkpoint inhibitors to treat solid tumors.

Industry: Health Care

Latest Trade: $12.59 0.00 (0.0%)

First Day Return: -5.0%

Return from IPO: -16.1%

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. Our lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. In January 2016, we began enrolling patients in a large expansion cohort trial for CPI-444. This Phase 1/1b clinical trial is designed to examine safety, tolerability, biomarkers and preliminary efficacy of CPI-444 in several solid tumor types, both as a single agent and in combination with Genentech, Inc.'s investigational cancer immunotherapy, atezolizumab, a fully humanized monoclonal antibody targeting PDL-1. We have a lead development candidate for our second program, an anti-CD73 monoclonal antibody that inhibits the production of adenosine, and plan to select development candidates for our other two programs in 2016. We believe the breadth and status of our pipeline demonstrates our management team's expertise in understanding and developing immuno-oncology assets as well as in identifying product candidates that can be in-licensed and further developed internally to treat many types of cancer. We hold worldwide rights to all of our product candidates.
more less
IPO News for Corvus Pharmaceuticals
more
IPO Data
IPO File Date 01/04/2016
Offer Price $15.00
Price Range $15.00 - $17.00
Offer Shares (mm) 4.7
Deal Size ($mm) $71
IPO Data
IPO Date 03/22/2016
Offer Price $15.00
Price Range $15.00 - $17.00
Offer Shares (mm) 4.7
Deal Size ($mm) $71
Underwriters
more
Company Data
Headquarters Washington, DC
Founded 2014
Employees 33
Website www.corvusbiotech.com